Delayed dermatologic hypersensitivity reaction secondary to ipilimumab

Journal of Immunotherapy

Volumn 38, Issue 4, 2015, Pages 165-166

  Ludlow, Steven P ^a   Kay, Noriko ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

hypersensitivity; ipilimumab; melanoma; rash; toxicity

Indexed keywords

ADRENALIN; DEXAMETHASONE; DIPHENHYDRAMINE; HYDROCODONE BITARTRATE PLUS PARACETAMOL; IPILIMUMAB; METHYLPREDNISOLONE; NAPROXEN; PARACETAMOL; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; MONOCLONAL ANTIBODY;

ADULT; ARM; ARTHRALGIA; CANCER PATIENT; CANCER SURGERY; CASE REPORT; DELAYED HYPERSENSITIVITY; DISEASE SEVERITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; EOSINOPHIL COUNT; ERYTHEMA; FEMALE; HISTOPATHOLOGY; HOSPITAL READMISSION; HOSPITALIZATION; HUMAN; LABORATORY TEST; LYMPH NODE DISSECTION; MELANOMA; MULTIPLE CYCLE TREATMENT; PHOTOGRAPHY; PHYSICAL EXAMINATION; PRIORITY JOURNAL; PRURITUS; SHORT SURVEY; SKIN DISEASE; SKIN REDNESS; TELECONSULTATION; TREATMENT OUTCOME; ADVERSE EFFECTS; CANCER STAGING; HYPERSENSITIVITY, DELAYED; IMMUNOLOGY; IMMUNOTHERAPY; METASTASIS; SKIN NEOPLASMS;

ADULT; ANTIBODIES, MONOCLONAL; CTLA-4 ANTIGEN; DEXAMETHASONE; DRUG HYPERSENSITIVITY; EPINEPHRINE; FEMALE; HUMANS; HYPERSENSITIVITY, DELAYED; IMMUNOTHERAPY; MELANOMA; NEOPLASM METASTASIS; NEOPLASM STAGING; PRURITUS; SKIN NEOPLASMS;

EID: 84928480844     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/CJI.0000000000000076     Document Type: Short Survey

References (12)

1. Garbe C, Eigentler TK, Keilholz U, et al. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011; 16: 5-24.
2. Melero I, Hervas-Stubbs S, Glennie M, et al. Immunostimulatory monoclonal antibodies for cancer therapy. Nat Rev Cancer. 2007; 7: 95-106.
3. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 211-223.
4. Egen JG, Kuhns MS, Allison JP. CTLA-4: new insights into its biological function and use in tumor immunotherapy. Nat Immunol. 2002; 3: 611-618.
5. Chikuma S, Bluestone JA. CTLA-4 and tolerance: the biochemical point of view. Immunol Res. 2003; 28: 241-253.
6. Sanderson K, Scotland R, Lee P, et al. Autoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanoma. J Clin Oncol. 2005; 23: 741-750.
7. Attia P, Phan GQ, Maker AV, et al. Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. J Clin Oncol. 2005; 23: 6043-6053.
8. Beck KE, Blansfield JA, Tran KQ, et al. Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen
9. J Clin Oncol. 2006; 24: 2283-2289.
10. Sinha R, Edmonds K, Newton-Bishop JA, et al. Cutaneous adverse events associated with vemurafenib in patients with metastatic melanoma: practical advice on diagnosis, prevention and management of the main treatment-related skin toxicities. Br J Dermatol. 2012; 167: 987-994.
11. Wolchok JD, Hoos A, O'Day S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15: 7412-7420.
12. Weber J, Hamid O, Amin A, et al. Randomized phase I pharmacokinetic study of ipilimumab with or without one of two different chemotherapy regimens in patients with untreated advanced melanoma. Cancer Immun. 2013; 13: 7-16.